MedinCell S.A. (EPA:MEDCL)

France flag France · Delayed Price · Currency is EUR
23.46
+1.06 (4.73%)
Sep 29, 2025, 2:44 PM CET
4.73%
Market Cap741.30M
Revenue (ttm)27.73M
Net Income (ttm)-18.44M
Shares Out33.09M
EPS (ttm)-0.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume107,477
Average Volume133,749
Open22.74
Previous Close22.40
Day's Range22.38 - 23.46
52-Week Range12.00 - 23.46
Beta1.11
RSI81.42
Earnings DateDec 9, 2025

About MedinCell

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 131
Stock Exchange Euronext Paris
Ticker Symbol MEDCL
Full Company Profile

Financial Performance

In 2024, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2023.

Financial Statements

News

Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed

(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting olanzapi...

7 days ago - Nasdaq

Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia

Update on the completion of pivotal phase 3 trial for olanzapine Long-Acting Injectable in schizophrenia by Medincell's partner Teva Pharmaceuticals.

8 months ago - Seeking Alpha